Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

ABSTRACT: BACKGROUND: Lanreotide is a long-acting somatostatin analogue with proven antitumour effects against well-differentiated (WD) gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). However, there are no globally established prognostic factors associated with the efficacy of lanreotide a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EJNMMI Res
Autors principals: Kim, Yong-il, Yoo, Changhoon, Oh, Seung Jun, Lee, Sang Ju, Kang, Junho, Hwang, Hee-Sang, Hong, Seung-Mo, Ryoo, Baek-Yeol, Ryu, Jin-Sook
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7295884/
https://ncbi.nlm.nih.gov/pubmed/32542576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-020-00651-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars